Lidocaine/prilocaine - Plethora Solutions

Drug Profile

Lidocaine/prilocaine - Plethora Solutions

Alternative Names: Fortacin; Prilocaine Lidocaine Plethora; Prilocaine/lidocaine; PSD-502; Tempe

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plethora Solutions
  • Class Acetanilides; Anilides; Erectile dysfunction therapies; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Premature ejaculation
  • Discontinued Pain

Most Recent Events

  • 06 Jul 2018 Plethora Solutions plans a phase II trial for Premature ejaculation in USA (Topical) (NCT03578783)
  • 11 Nov 2016 Launched for Premature ejaculation in United Kingdom (Topical)
  • 15 May 2015 Lidocaine/prilocaine is still in active development for Premature ejaculation in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top